Healthcare Industry News:  Accuray 

Devices Oncology

 News Release - March 7, 2006

Clinicians Embrace the CyberKnife(R) Robotic Radiosurgery System for the Treatment of Extracranial Tumors

Extracranial Tumor Treatments - Led by the Treatment of Tumors in the Lungs - Now Represent More Than 50 Percent of All US CyberKnife Procedures

SUNNYVALE, Calif., March 7 (HSMN NewsFeed) -- Accuray Incorporated, the global leader in the field of robotic radiosurgery, announced today that clinicians worldwide are using the CyberKnife® Robotic Radiosurgery System to treat tumors outside the head at a rapidly increasing rate. Extracranial tumor treatment now represents more than 50 percent of all procedures performed with the CyberKnife System in the United States, with the treatment of lung tumors outpacing all other tumor treatments in the body. Since the July 2004 introduction of the Synchrony(TM) Respiratory Tracking System, lung tumor treatments have increased threefold annually.

"The CyberKnife System is the only radiosurgery system available to clinicians today that supports our need to treat tumors anywhere in the body -- particularly in patients with tumors that move with respiration," said Dr. Eric D. Anderson, assistant professor of medicine in the division of pulmonary, critical care and sleep study, Georgetown University Hospital. "The addition of the Synchrony System has played a critical role in the accurate and effective radiation treatment of inoperable patients."

The introduction of the Synchrony System, a respiratory tracking system unique to the CyberKnife, has contributed to the surge in CyberKnife System adoption for the treatment of tumors in the lung and other parts of the anatomy that move with respiration. Synchrony allows patients to breathe normally throughout their treatment without uncomfortable breath-holding or radiation beam gating techniques so clinicians can track, detect and correct for tumor and patient movement throughout the treatment minimizing damage to healthy tissue or critical structures.

"Clinicians have clearly embraced the CyberKnife System as a unique and valuable tool to treat tumors anywhere in the body, particularly in an area such as the lung where tracking tumors with sub-millimeter accuracy is critical," said Eric Lindquist, chief marketing officer of Accuray. "As more clinical studies are published regarding the effectiveness of the CyberKnife System in treating tumors of the spine, lung, pancreas, liver and prostate, we expect the rate of extracranial procedures to continue to grow worldwide."

About the CyberKnife® Robotic Radiosurgery System

The CyberKnife System is the world's first and only radiosurgery system that utilizes intelligent robotics to treat tumors anywhere in the body. The CyberKnife System treats patients in single or staged (typically 2-5) sessions by delivering multiple beams of precisely directed radiation that converge upon the tumor while minimizing injury to surrounding healthy tissue. Image guidance and computer controlled robotics combine to continuously track, detect and correct for tumor and patient movements throughout the treatment with sub-millimeter accuracy. Because of this extreme precision and accuracy, no head or body frame is required. The CyberKnife has proven to attract a new patient population to a physician's practice and complements existing radiation therapy, IMRT or IGRT programs.

About Accuray Inc.

Accuray Inc., a privately held company based in Sunnyvale, Calif., is the global leader in the field of robotic radiosurgery. Its CyberKnife System is the world's first and only intelligent robotic radiosurgery system designed to treat tumors anywhere in the body with sub-millimeter accuracy. More than 100 CyberKnife Systems have been purchased by leading medical centers throughout the world and a large body of peer-reviewed papers supports its clinical practice. To date, the CyberKnife has treated more than 18,000 patients worldwide. For more information, please visit www.Accuray.com.

For media inquiries, please contact Jeff Speer at jspeer@fischerhealth.com or 310-577-7870, ext. 156.

©2006 All rights reserved. Accuray, the Accuray logo, and CyberKnife are among trademarks or registered trademarks of Accuray Inc.


Source: Accuray

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.